[Primary drug resistance of Mycobacterium tuberculosis to antitubercular drugs and its clinical significance]. 1975

O M Ianovskaia, and A N Poliakova, and I D Samuliak, and G V Vasilik

UI MeSH Term Description Entries
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D014397 Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung. Pulmonary Consumption,Pulmonary Phthisis,Pulmonary Tuberculoses,Pulmonary Tuberculosis,Tuberculoses, Pulmonary,Consumption, Pulmonary,Consumptions, Pulmonary,Phthises, Pulmonary,Phthisis, Pulmonary,Pulmonary Consumptions,Pulmonary Phthises

Related Publications

O M Ianovskaia, and A N Poliakova, and I D Samuliak, and G V Vasilik
March 1988, JPMA. The Journal of the Pakistan Medical Association,
O M Ianovskaia, and A N Poliakova, and I D Samuliak, and G V Vasilik
November 2004, The Indian journal of medical research,
O M Ianovskaia, and A N Poliakova, and I D Samuliak, and G V Vasilik
January 1995, Problemy tuberkuleza,
O M Ianovskaia, and A N Poliakova, and I D Samuliak, and G V Vasilik
January 2002, Archiv der Pharmazie,
O M Ianovskaia, and A N Poliakova, and I D Samuliak, and G V Vasilik
February 1980, Problemy tuberkuleza,
O M Ianovskaia, and A N Poliakova, and I D Samuliak, and G V Vasilik
June 1989, Medicina clinica,
O M Ianovskaia, and A N Poliakova, and I D Samuliak, and G V Vasilik
February 1990, Medicina clinica,
O M Ianovskaia, and A N Poliakova, and I D Samuliak, and G V Vasilik
March 1999, Revista clinica espanola,
O M Ianovskaia, and A N Poliakova, and I D Samuliak, and G V Vasilik
January 1974, Problemy tuberkuleza,
O M Ianovskaia, and A N Poliakova, and I D Samuliak, and G V Vasilik
January 1971, Problemy tuberkuleza,
Copied contents to your clipboard!